Analysts Set Masimo Co. (MASI) Target Price at $139.13

Shares of Masimo Co. (NASDAQ:MASI) have earned a consensus rating of “Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $139.13.

Several analysts have recently issued reports on the stock. BidaskClub lowered shares of Masimo from a “strong-buy” rating to a “buy” rating in a research report on Friday. BTIG Research lowered shares of Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target on the stock. in a research report on Tuesday, April 16th. Needham & Company LLC reissued a “buy” rating on shares of Masimo in a research report on Tuesday, April 9th. Piper Jaffray Companies reissued an “overweight” rating and issued a $140.00 price target on shares of Masimo in a research report on Wednesday, February 27th. Finally, Zacks Investment Research raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd.

In related news, insider Jon Coleman sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $140.00, for a total transaction of $280,000.00. Following the sale, the insider now owns 13,201 shares of the company’s stock, valued at approximately $1,848,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the sale, the director now directly owns 74,832 shares in the company, valued at approximately $10,102,320. The disclosure for this sale can be found here. Insiders have sold a total of 35,722 shares of company stock worth $4,832,310 in the last ninety days. 11.50% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. grew its stake in Masimo by 20.9% in the 4th quarter. Meeder Asset Management Inc. now owns 9,071 shares of the medical equipment provider’s stock worth $973,000 after buying an additional 1,569 shares in the last quarter. Piedmont Investment Advisors Inc. grew its stake in Masimo by 41.9% in the 4th quarter. Piedmont Investment Advisors Inc. now owns 4,631 shares of the medical equipment provider’s stock worth $497,000 after buying an additional 1,368 shares in the last quarter. Fundsmith LLP purchased a new position in Masimo in the 4th quarter worth approximately $51,470,000. Round Table Services LLC purchased a new position in Masimo in the 1st quarter worth approximately $221,000. Finally, First Hawaiian Bank grew its stake in Masimo by 170.0% in the 4th quarter. First Hawaiian Bank now owns 1,080 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 680 shares in the last quarter. 83.88% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ MASI traded up $0.18 during midday trading on Thursday, hitting $122.47. The company’s stock had a trading volume of 791,180 shares, compared to its average volume of 495,935. Masimo has a one year low of $88.09 and a one year high of $141.05. The firm has a market cap of $6.53 billion, a P/E ratio of 40.42, a price-to-earnings-growth ratio of 2.55 and a beta of 1.19.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.11. Masimo had a net margin of 22.55% and a return on equity of 19.53%. The company had revenue of $223.10 million for the quarter, compared to analyst estimates of $220.96 million. During the same quarter in the previous year, the firm posted $0.72 earnings per share. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, equities research analysts expect that Masimo will post 3.08 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: Consumer behavior in bull markets

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.